Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | PPARG | P37231 | 8/20 | 0.45 |
| ▸ | PPARA | Q07869 | 7/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | PPARD | Q03181 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4826525 | 0.85 | KDM4E (0.45) | KDM4ERAB9APPARGPPARARXFP1 | |
| SCHEMBL5368869 | 0.84 | KDM4E (0.47) | KDM4ERAB9APPARGPPARARXFP1 | |
| SCHEMBL27618546 | 0.83 | KDM4E (0.48) | KDM4ERAB9APPARGPPARARXFP1 | |
| SCHEMBL1048006 | 0.82 | TP53 (0.49) | KDM4ERAB9ARXFP1POLBSMN1; SMN2 | |
| SCHEMBL4830096 | 0.80 | TARBP2 (0.50) | KDM4ERAB9APPARGPPARARXFP1 | |
| SCHEMBL4830153 | 0.80 | HSD17B10 (0.53) | KDM4EPPARAPOLBMAPTSMN1; SMN2 | |
| SCHEMBL1051419 | 0.80 | KDM4E (0.60) | KDM4ERAB9APPARGPPARAHRH3 | |
| SCHEMBL1049626 | 0.80 | ALDH1A1 (0.51) | KDM4ERAB9APPARGPPARAPOLB | |
| SCHEMBL1047012 | 0.79 | KDM4E (0.64) | KDM4ERAB9APPARGPPARAFFAR1 | |
| SCHEMBL1051790 | 0.77 | NOTUM (0.45) | KDM4ERAB9APPARGPPARAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7399777-B2 | Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmceuticals | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-07-15 | — | — | US | disclosed |
| US-20050267177-A1 | Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmaceuticals | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2005-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050267177-A1 | Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmaceuticals | PNLIP, LIPC, LIPA | KDM4E 2111/4885RAB9A 2345/4885PPARG 290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.